Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC.
S. Pak
No relevant relationships to disclose
M. Reed
No relevant relationships to disclose
M. Luther
No relevant relationships to disclose
M. Averia
No relevant relationships to disclose
S. Desai
No relevant relationships to disclose
J. K. Pinski
No relevant relationships to disclose
T. B. Dorff
No relevant relationships to disclose
D. I. Quinn
No relevant relationships to disclose
B. Chan
No relevant relationships to disclose